NSF PAR Search | NSF Public Access Repository

Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher. Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?

Some links on this page may take you to non-federal websites. Their policies may differ from this site.

Deoxyribonucleic Acid-Based Polyvalent Ligand–Receptor Binding for Engineering the Cell Surface with Nanoparticles

https://doi.org/10.1021/acs.biomac.3c00264

Davis, Brandon; Lee, Kyungsene; Wang, Xuelin; Wang, Yong (July 2023, Biomacromolecules)

Full Text Available
Synthetic DNA for Cell Surface Engineering: Experimental Comparison between Click Conjugation and Lipid Insertion in Terms of Cell Viability, Engineering Efficiency, and Displaying Stability

https://doi.org/10.1021/acsami.1c22774

Wang, Xuelin; Wen, Connie; Davis, Brandon; Shi, Peng; Abune, Lidya; Lee, Kyungsene; Dong, Cheng; Wang, Yong (January 2022, ACS Applied Materials & Interfaces)

Full Text Available
In Situ Synthesis of an Aptamer‐Based Polyvalent Antibody Mimic on the Cell Surface for Enhanced Interactions between Immune and Cancer Cells

https://doi.org/10.1002/anie.202004206

Shi, Peng; Wang, Xuelin; Davis, Brandon; Coyne, James; Dong, Cheng; Reynolds, Joshua; Wang, Yong (May 2020, Angewandte Chemie International Edition)

Abstract An ability to promote therapeutic immune cells to recognize cancer cells is important for the success of cell‐based cancer immunotherapy. We present a synthetic method for functionalizing the surface of natural killer (NK) cells with a supramolecular aptamer‐based polyvalent antibody mimic (PAM). The PAM is synthesized on the cell surface through nucleic acid assembly and hybridization. The data show that PAM has superiority over its monovalent counterpart in powering NKs to bind to cancer cells, and that PAM‐engineered NK cells exhibit the capability of killing cancer cells more effectively. Notably, aptamers can, in principle, be discovered against any cell receptors; moreover, the aptamers can be replaced by any other ligands when developing a PAM. Thus, this work has successfully demonstrated a technology platform for promoting interactions between immune and cancer cells.
more » « less

Search for: All records